APA (7th ed.) Citation

Goldsmith, C., Plowman, P. N., Green, M. M., Dale, R. G., & Price, P. M. (2018, October). Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: Scope for dose escalation and lessons for toxicity. Radiation Oncology.

Chicago Style (17th ed.) Citation

Goldsmith, Christy, P. Nicholas Plowman, Melanie M. Green, Roger G. Dale, and Patricia M. Price. "Stereotactic Ablative Radiotherapy (SABR) as Primary, Adjuvant, Consolidation and Re-treatment Option in Pancreatic Cancer: Scope for Dose Escalation and Lessons for Toxicity." Radiation Oncology Oct. 2018.

MLA (9th ed.) Citation

Goldsmith, Christy, et al. "Stereotactic Ablative Radiotherapy (SABR) as Primary, Adjuvant, Consolidation and Re-treatment Option in Pancreatic Cancer: Scope for Dose Escalation and Lessons for Toxicity." Radiation Oncology, Oct. 2018.